A Randomized, Double-Blind, Placebo and Positive Drug-Controlled, Single-Dose, Dose-Escalation Phase I Clinical Study of GenSci134 Injection in Healthy Adults
Latest Information Update: 18 Jul 2025
At a glance
- Drugs GenSci 134 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 08 Jul 2025 Status changed from not yet recruiting to recruiting.
- 20 Jun 2025 New trial record